Niox Reports Strong Financial Performance and Potential Acquisition Talks

AIM-listed medical device company Niox Group has reported a robust financial performance for 2024, with a 14% revenue increase to £41.8 million. This growth, alongside a 21% rise in Adjusted EBITDA, marks a healthy trajectory for the company. Furthermore, Niox is in preliminary discussions with Keensight Capital regarding a potential all-cash acquisition proposal at 81p per share, showcasing strong interest in the firm’s promising future.

Niox Group, known for its advancements in asthma diagnostics, sold 6.3 million Niox FeNO tests in 2024 – a 19% increase from the previous year. The revenue boost was driven by an 11% rise in clinical revenue, reflecting strong market demand. The company is not only focused on financial growth but also on innovative product development. It is advancing its next-generation Niox PRO device, scheduled for a late 2025 launch, and expanding its manufacturing capabilities in collaboration with its sensor manufacturer. This forward-looking approach reaffirms Niox’s commitment to healthcare innovation. 

Executive Chairman Ian Johnson highlighted 2024 as a successful year, with revenue growth across all regions, particularly in the Asia-Pacific. While discussions with Keensight Capital are still in the early stages, Niox’s financial performance and strategic initiatives signal a company poised for future success. The potential acquisition and new product developments could drive further progress in the life sciences sector, underlining Niox’s influential role in advancing healthcare technology.

For the latest updates and in-depth insights into the world of Service Engineering, including breakthrough treatments, industry trends, and regulatory news, contact James Dolan today!